---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-096337"
form_type: "8-K"
ticker: "BRTX"
cik: "0001505497"
company_name: "BioRestorative Therapies, Inc."
filed_at: "2026-09-01T22:09:03+00:00"
generated_at: "2026-09-02T10:05:45.067290+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioRestorative appoints Mika Grasso interim CEO, Anna Skowron CFO; dismisses auditor CBIZ

## Summary
- Katharyn Field steps down as interim CEO/CFO, resigns from board; consulting deal with EEAK at $10k/month.
- Mika Grasso appointed interim CEO effective Aug 26, 2026; consulting deal with Currensea Capital at $10k/month.
- Anna Skowron appointed CFO effective Aug 27, 2026; consulting deal with BPC Consulting at $12k/month.
- Dismissed CBIZ as auditor, engaged Bush & Associates CPA; CBIZ report had going concern explanatory paragraph.
- No disagreements with CBIZ on accounting principles; audit committee changes: Steven Brown named chair.

## SEC filing metadata
- accession: 0001213900-26-096337
- form_type: 8-K
- ticker: BRTX
- cik: 0001505497
- company_name: BioRestorative Therapies, Inc.
- filed_at: 2026-09-01T22:09:03+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 4.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1505497/000121390026096337/0001213900-26-096337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505497/000121390026096337/ea0304309-8k_biore.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-096337
- JSON: https://secwatch.observer/filing/0001213900-26-096337.json
- Plain text: https://secwatch.observer/filing/0001213900-26-096337.txt

## Key facts
- Executive change
  Mika Grasso was appointed as Interim Chief Executive Officer at BioRestorative Therapies, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: On August 26, 2026, the Board appointed Mika Grasso as the Company’s Interim Chief Executive Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1505497/000121390026096337/0001213900-26-096337-index.htm
- Executive change
  Katharyn Field departed as Chief Financial Officer at BioRestorative Therapies, Inc..
  - Action: ceased to serve
  - Role: Chief Financial Officer
  source text: Ms. Field also ceased to serve as the Company’s interim Chief Financial Officer and Treasurer effective August 27, 2026, upon the appointment of her successor as described below
  evidence_url: https://www.sec.gov/Archives/edgar/data/1505497/000121390026096337/0001213900-26-096337-index.htm
- Executive change
  Katharyn Field departed as Interim Chief Executive Officer at BioRestorative Therapies, Inc..
  - Action: stepped aside
  - Role: Interim Chief Executive Officer
  source text: On August 26, 2026, Katharyn Field advised the Board that she wished to step aside as the Company’s Interim Chief Executive Officer and Chief Financial Officer, and the Board accepted her request effective as of that date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1505497/000121390026096337/0001213900-26-096337-index.htm
- Executive change
  Steven Brown was appointed as Chairman of the Board at BioRestorative Therapies, Inc..
  - Action: appointed
  - Role: Chairman of the Board
  source text: On September 1, 2026, the Board also appointed Mr. Brown as Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1505497/000121390026096337/0001213900-26-096337-index.htm
- Executive change
  Katharyn Field resigned as Director at BioRestorative Therapies, Inc..
  - Action: resigned
  - Role: Director
  source text: and resigned as a member of the Board effective August 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1505497/000121390026096337/0001213900-26-096337-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.